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Abstract
Introduction: A high-altitude environment causes appetite loss in unacclimatised humans, leading to weight reduction. Ghrelin, cholecystokinin 
(CCK), and glucagon like peptide-1 (GLP-1), are gut hormones involved in the regulation of food intake and energy metabolism. The liver is an 
important site of metabolic regulation, and together with the gut it plays a role in food intake regulation. This study intends to study the time-
dependent changes occurring in plasma gut hormones, PPARα, PPARδ, and PGC1α, in the stomach and liver during hypoxia. 
Material and methods: Male Sprague Dawley rats were exposed to hypobaric hypoxia in a decompression chamber at 7620 m for differ-
ent durations up to seven days. 
Results: Hypoxia increased circulating ghrelin from the third day onwards while CCK and GLP-1 decreased immediately. An increase in 
ghrelin, ghrelin receptor protein levels, and GOAT mRNA levels in the stomach was observed. Stomach cholecystokinin receptor (CCKAR), 
PPARα, and PPARδ decreased. Liver CCKAR decreased during the first day of hypoxia and returned to normal levels from the third day 
onwards. PPARα and PGC1α expression increased while PPARδ protein levels reduced in the liver on third day. 
Conclusion: Hypoxia alters the expression of ghrelin and ghrelin receptor in the stomach, CCKAR in the liver, and PPAR and its cofactors, 
which might be possible role players in the contribution of gut and liver to anorexia at high altitude. (Endokrynol Pol 2015; 66 (4): 334–341)
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Streszczenie
Wstęp: Przebywanie na dużej wysokości powoduje utratę apetytu u osób do tego nieprzystosowanych i prowadzi do redukcji masy 
ciała. Grelina, cholecystokinina (CCK) i peptyd glukagonopodobny 1 (GLP-1) są hormonami przewodu pokarmowego biorącymi udział 
w regulacji przyjmowania pokarmu i metabolizmu energii. Wątroba stanowi ważne miejsce regulacji metabolicznej i razem z jelitem 
spełnia istotną funkcję w regulacji przyjmowania pokarmu. Niniejsze badanie miało na celu ocenę zmian zależnych od czasu w stężeniu 
hormonów przewodu pokarmowego oraz ekspresji PPARα, PPARδ oraz PGC1α w żołądku i wątrobie występujących podczas hipoksji.
Materiał i metody: Szczury Sprague Dawley płci męskiej poddano działaniu hipoksji hipobarycznej w komorze dekompresyjnej na 
wysokości 7620 m. Pobyty w komorze różniły się czasem trwania, do maksymalnie 7 dni. 
Wyniki: Hipoksja podwyższała stężenie krążącej greliny od trzeciego dnia pobytu z komorze do końca jego trwania, podczas gdy stęże-
nia CCK i GLP-1 uległy natychmiastowemu obniżeniu. Zaobserwowano podwyższenie stężenie greliny, białka receptora greliny i GOAT 
mRNA w żołądku. W żołądku ekspresja receptorów cholecystokininy (CCKAR), PPARα i PPARδ uległy obniżeniu. stężenie wątrobowego 
CCKAR uległ obniżeniu pierwszego dnia wystąpienia hipoksji, powrócił do prawidłowego stężenia trzeciego dnia i pozostał prawidłowy 
do końca pobytu w komorze. Ekspresje PPARα i PGC1α wzrosły, podczas gdy stężenie białka PPARδ uległo obniżeniu w wątrobie.
Wnioski: Hipoksja zmienia ekspresję greliny oraz receptora greliny w żołądku, CCKAR w wątrobie i PPAR oraz jego kofaktory, które mogą 
odgrywać rolę w przyczynianiu się jelit i wątroby do anoreksji przy przebywaniu na dużej wysokości. (Endokrynol Pol 2015; 66 (4): 334–341)
Słowa kluczowe: grelina; CCK; GLP-1; anoreksja; hipoksja
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Introduction
Anorexia, one of the complications experienced at high 
altitude, is due to hypoxia-induced disturbances in 
the peripheral signals that indicate energy status and 
control appetite. Hormones secreted from the gastro-
intestinal tract play an important role as an endocrine 
signal by sensing the nutrient composition and thus 
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influencing the control of hunger and satiation by the 
hypothalamus through specific receptors. The gut plays 
an important role in energy balance through the release 
of appetite regulatory hormones like ghrelin, cholecys-
tokinin (CCK), and glucagon-like peptide-1 (GLP1) 
[1]. In humans as well as animals ghrelin is known to 
stimulate food intake, increase in fat mass, and decrease 
in fat utilisation [2–4]. Ghrelin, the only known periph-
eral orexigenic hormone, is mainly secreted from the 
fundus region of the stomach, exists in unacylated and 
active acylated forms, and is a ligand for the growth 
hormone secretagogue (GHS) receptor [5]. Ghrelin 
exerts its orexigenic action through GHS receptor in the 
hypothalamus and also by inhibiting vagal afferent neu-
rons in the periphery [2, 6]. Ghrelin O-acyltransferase 
(GOAT) facilitates the acylation of ghrelin at serine-3 
residue, which is essential for its binding to the growth 
hormone secretagogue receptor to exert its action on 
appetite [7]. A decrease in plasma ghrelin level [8] and 
both increase and decrease in plasma CCK have been 
reported in humans exposed to high altitude [9, 10]. 
CCK inhibits feeding by acting on the cholecystokinin A 
receptor (CCKAR) in the gastrointestinal tract [11]. The 
importance of peripheral CCKAR receptor in regulating 
food intake has been demonstrated in a study in rats 
by Reidelberger et al. [12]. GLP-1 is a secretory peptide 
derived from proglucagon mainly from the gut and 
also from the brain [13]. It is an anorectic peptide that 
suppresses food intake upon peripheral administration 
[14]. It exerts its action via a widely expressed G-protein 
coupled receptor, GLP-1R [15]. CCK and GLP-1 excite 
vagal afferent neurons to inhibit food intake [6]. CCK 
and GLP-1 are secreted into circulation upon food 
ingestion from the gut [1]. Insulin increases in circu-
lation to decrease plasma glucose before a meal, and 
a delay in food intake has been observed when there is 
no decrease in glucose [11]. Hence, it can be assumed 
that hypobaric hypoxia may alter these circulating gut 
hormones, which may in part contribute to anorexia.
Peroxisome proliferator-activated receptors (PPAR) 
are a family of nuclear receptors involved in various cel-
lular processes including stress response and regulation 
of genes involved in energy homeostasis. Fatty acids 
and other lipid metabolites are their activating ligands. 
There are three isoforms of PPAR (α, δ, and γ), which 
are differentially expressed in various tissues. PPARα 
is expressed in liver, heart, and muscle while PPARδ 
is expressed ubiquitously [16]. PGC1α and PGC1β are 
cofactors of PPARγ and they play an important role in 
many cellular pathways. The liver is a vital organ in 
maintaining blood glucose at the optimal level during 
fasting as well as in the fed state. Since glucose is one 
of the satiety factors it is important to maintain glucose 
homeostasis during hypoxia [17]. PGC1α and PGC1β 
both play a role in regulating glucose uptake and re-
lease from liver. PGC-1α expression is rapidly induced 
in the liver during fasting, a process that is mediated 
by cAMP and glucocorticoid signalling pathways [18]. 
Similarly, a fasting-induced increase in PGC1β in liver 
has also been reported, but their targets seem to be 
gluconeogenesis for PGC1α and fatty acid oxidation 
for PGC1β [19]. Hence, the present study was aimed 
at identifying the effect of hypobaric hypoxia on cir-
culating ghrelin, CCK, and GLP-1, and the molecular 
changes in the stomach and liver during different dura-
tions of hypoxia in relation to anorexia as an attempt 
to explore potential targets for improving food intake 
of lowlanders at high altitude.
Material and methods
Material
Enzyme-linked immunosorbent assay (ELISA) kits 
for ghrelin (CSB-E13167r), CCK (CSB-E08114r), and 
GLP-1 (CSB-E08117r) were purchased from Cusabio, 
China. A glucose estimation kit was purchased from 
AutoSpan diagnostics Ltd, India. Anti-ghrelin (ab15861), 
anti-ghrelin receptor (ab85104), anti-CCKAR (ab75153), 
anti-PPARα (ab2779), anti-PPARδ (ab23673) primary 
antibodies, and anti-rabbit/mouse horseradish peroxi-
dase (HRP) conjugated secondary antibodies (ab97051, 
ab97023) were purchased from Abcam, Inc. First strand 
cDNA synthesis kit and other PCR reagents were pur-
chased from Fermentas, USA. Primers were synthesised 
by Eurofins Genomics, India. β-actin primary antibody 
(A1978), Trizol, Bicinchoninic acid, and all other chemi-
cals were purchased from Sigma Aldrich Co, LLC.
Animals
Male Sprague Dawley rats weighing 150–200 g were 
obtained from the animal breeding facility of the in-
stitute in which the study was undertaken. They were 
fed ad libitum with standard laboratory rodent’s chow 
and allowed free access to drinking water. Animals were 
maintained under laboratory conditions in a controlled 
environment of temperature 28 ± 2°C and 12-hour light/ 
/dark cycle as per Committee for the Purpose of Control 
and Supervision of Experiments on Animals (CPCSEA) 
guidelines, and the study protocol was approved by the 
institutional Animal Ethics Committee.
Grouping of animals and hypoxia exposure
The experimental rats were divided into six groups with 
six animals in each group. Groups were named accord-
ing to the time of hypoxic exposure: Control, 6 h, 12 h, 
24 h, 3 day, and 7 day. Except for the control group all 
of the other groups were exposed to hypobaric hypoxia 
at a simulated altitude of 7620 m, pressure equivalent to 
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282 mm Hg, with an air flow of 0.8 L/min/rat into the hy-
pobaric chamber. The temperature of the chamber was 
maintained 28 ± 2oC with relative humidity 55 ± 2%. 
Every day at 10:00 A.M. the chamber was opened to 
replenish food and water. All animals were fasted over-
night and sacrificed by administering a lethal dose of 
xylazine (10 mg/kg body wt.) and ketamine (100 mg/kg 
body wt.) intraperitoneally. Blood was drawn by car-
diac puncture, collected into heparinised tubes, and 
centrifuged at 1000 g for 15 minutes to separate plasma. 
Plasma samples were stored at –80°C until analysis. 
Whole stomach tissues and liver tissues collected for 
western blot analysis were stored at –80˚C until use. 
Around 100 mg of the liver tissues were stored in RNA 
Later solution at –20°C for RNA isolation.
Food intake and body weight measurements
Two groups with 12 animals each were kept for body 
weight and food intake measurements. One group was 
a normoxia control and the other group was exposed to 
hypoxia for seven days. Both groups of animals were 
monitored for their food intake and body weight every 
24 hours for seven days. Food intake and body weight 
of the hypoxia-exposed group were monitored every 
day at 10 A.M. while the chamber was open for food and 
water replenishment. Data was analysed by calculating 
the percentage change.
Quantification of plasma ghrelin, CCK, GLP-1, 
and glucose
Plasma ghrelin, CCK, and GLP-1 were quantified us-
ing ELISA kits as per the manufacturer’s instructions. 
100 µl of plasma was used for the test and quantified 
using Gen5 software by four-parameter logistic analy-
sis. Plasma glucose was estimated by glucose oxidase 
method following the manufacturer’s instructions.
Western blotting
Stomach and liver tissue homogenates were made in 
RIPA buffer and centrifuged at 16000 g for 20 minutes, 
after which the supernatant was estimated for protein 
content by bicinchoninic acid assay. The stomach and liver 
tissue protein extracts (40 μg) of all groups were resolved 
in polyacrylamide gel and transferred to polyvinylidene 
fluoride (PVDF) membrane for blotting. The transferred 
blots of stomach tissues were incubated with anti-pre-
proghrelin, anti-ghrelin receptor, anti-CCKAR, anti-
PPARα, anti-PPARδ, and anti-β-actin primary antibodies, 
respectively, overnight at 4°C. The blots of liver tissues 
were incubated with anti-CCKAR, anti-PPARδ, and anti-
β-actin primary antibodies, respectively, overnight at 4°C. 
Following incubation with primary antibodies, blots were 
incubated with anti-rabbit/mouse horseradish peroxidase 
(HRP) conjugated secondary antibody for two hours at 
room temperature for respective blots. The blots were 
developed using diaminobenzidine as a substrate, and 
densitometry analysis was done using ImageJ software.
Semiquantitative reverse transcriptase  
polymerase chain reaction (PCR)
Total Ribonucleic Acid (RNA) was isolated from stom-
ach and liver tissue using TRIzol reagent according to 
the manufacturer’s protocol. RNA quality was checked 
by resolving in 1.0% agarose gel and visualised for 28S 
and 18S rRNA bands under UV light with ethidium 
bromide staining. RNA concentrations were quantified 
using a nanodrop spectrophotometer (Thermo Fisher 
Scientific, USA). Complementary deoxyribonucleic 
acid (cDNA) was prepared from 1 μg of total RNA of 
each sample as per kit protocol using a first strand 
cDNA synthesis kit. Specific primers for GOAT were 
designed using Primer Pick tool of NCBI, primers for 
PPARα and PGC1α were taken from a literature source 
[20, 21], and primers for Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were purchased from Fer-
mentas, USA (Table I). Amplification of specific cDNAs 
were carried out in 20 μl reaction mixture contain-
ing PCR buffer (750 mM Tris-HCL pH 8.8, 200 mM 
(NH4)2SO4, 0.1% Tween 20 and 20 mM MgCl2), 0.2 mM 
dNTP mix, 0.05 U/μL Taq polymerase enzyme, 1 μM of 
each forward and reverse primer and 1 μl of respective 
cDNA. The annealing temperatures used for different 
Table I. PCR primer sequences and annealing temperature
Tabela I. Sekwencje starterów PCR i temperatura annealingu
Gene Upper sequence (5´-3´) Lower sequence (5´-3´) Cycles Product (bps) Temperature 
(°C)
Reference
GOAT CCCCCTGTGAGGTTCTACATC TTGGTCTTTGAACGCAAGCC 35 247 60.0 NM001107317.2
PPARα GGTCAAGGCCCGGGTCATACTCG AAGCATTGCCGTACGCGATCAG 40 350 55.0 [20]
PGC1α GTGCAGCCAAGACTCTGTATGG GTCCAGGTCATTCACATCAAGTTC 35 124 58.0 [21]
GAPDH CAAGGTCATCCATGACAACTTTG GTCCACCACCCTGTTGCTGTAG 35 496 58.0 Fermentas, USA
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sets of primers are listed in Table I. All PCR products 
were resolved by electrophoresis using 1.5% agarose 
gel and stained with ethidium bromide; the images 
were captured under UV illumination, and densitom-
etry analysis was done using ImageJ software.
Statistical analysis
Data are expressed as mean ± SEM. Significant dif-
ferences were calculated for hypoxia-exposed groups 
against the control group using one-way ANOVA fol-
lowed by Dunnets’s t post hoc analysis using SPSS ver-
sion 22 (IBM Corporation). Statistical significance was 
set at P ≤ 0.05. The levels of significance are denoted in 
the figures as * P < 0.05, ** P < 0.01, and *** P < 0.001.
Results
Anorexia and weight loss during hypoxia
The body weight of hypoxia-exposed rats started de-
creasing from the first day onwards, and they continued 
to lose weight until the end of exposure (Fig. 1A). Ani-
mals when exposed to hypobaric hypoxia experienced 
anorexia with a reduction in food intake to 4.3% on the 
first day. By the end of exposure food intake improved 
to 53% of pre-exposure food intake (Fig. 1B). 
Hypoxia alters gut hormones of energy metabo-
lism and glucose in circulation
Exposure to hypoxia increased ghrelin levels in plasma 
on the third and seventh day compared to the con-
trol group (Fig. 2A). CCK and GLP-1 levels sharply 
decreased soon after exposing the rats to hypoxia at 
6 hours and remained low until the end of exposure 
(Fig. 2B, 2C). Hypoxia exposure lead to an increase in 
circulating glucose levels with maximum at 24-hour 
time point (Fig. 2D). 
Changes in stomach tissue during hypoxia
Pre-proghrelin increased to about 50% on exposure to 
hypoxia, and a 30% increase in ghrelin receptor was 
observed. GOAT mRNA levels rose from the third day of 
exposure. CCKAR protein was decreased from 24 hours 
until the end of hypoxia exposure. PPARα and PPARδ 
protein levels were decreased during hypoxia in the 
stomach with maximum reduction at 24 hours (Fig. 3).
Changes in liver tissue during hypoxia
On exposure to hypoxia CCKAR initially decreased to 
41% at 24 hours, which then increased to 113% by day 
seven. PPARδ increased at 6 hours and 12 hours but de-
creased below control at 24 hours and on the third day 
but on day seven increased to 140% (Fig. 4A). PPARα 
mRNA increased to 167% at 6 hours and remained high 
throughout the exposure. There was an increase in 
PGC1α mRNA on exposure to hypoxia (Fig. 4B). 
Discussion
The present study reports that exposure to high-
altitude hypoxia causes anorexia, and CCKAR, PPARs, 
and PGC1s in liver and stomach might be potential 
targets in alleviating anorexia. On exposure to hypoxia, 
circulating levels of ghrelin increased, but the increase 
was from the third day only. During the first day of 
Figure 1. Changes in food intake and body weight of rats during hypoxia exposure. A. Percentage change in body weight graph shows 
that hypoxia exposed rats lost around 23% of their initial weight by the end of exposure. B. Percentage change in food intake shows 
maximum reduction in food intake on the first day of exposure. *P < 0.05 versus control group at each time point
Rycina 1. Zmiany w przyjmowaniu pokarmu i masie ciała szczurów podczas poddania ich działaniu hipoksji. A. Wykres procentowej 
zmiany w masie ciała wskazuje, że szczury poddane działaniu hipoksji straciły około 23% początkowej masy ciała po ustaniu hipoksji. 
B. Procentowa zmiana w ilości przyjmowanego pokarmu ilustruje maksymalną redukcję przyjmowania pokarmu pierwszego dnia 
działania hipoksji. *P < 0,05 wobec grupy kontrolnej w każdym punkcie czasowym
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Figure 2. Plasma levels of hormones involved in appetite regulation. A. Plasma ghrelin levels increased during hypoxia. B. Plasma 
cholecystokinin (CCK). C. Plasma glucagon-like peptide-1 (GLP-1). Hypoxia exposure caused reduction in both CCK and GLP-1 levels 
in circulation. D. Plasma glucose levels increased during hypoxia exposure. *P < 0.05 versus unexposed group
Rycina 2. Stężenie hormonów w osoczu biorący udział w regulacji apetytu. A. Podwyższony poziom greliny w osoczu podczas 
hipoksji. B. Stężenie cholecystokininy (CCK) w osoczu. C. Stężenie glukagonopodobnego peptydu-1 (GLP-1) w osoczu. 
Hipoksja wywołała redukcję zarówno stężenia CCK, jak i GLP-1. D. Zwiększone stężenie glukozy w osoczu wywołane hipoksją. 
*P < 0,05 wobec grupy niewystawionej na działanie hipoksji
exposure circulating ghrelin remained the same as in 
controls even though the highest reduction in food 
intake was observed on day 1, indicating that fasting 
did not immediately induce ghrelin secretion, but from 
the third day ghrelin levels increased in response to 
decreased food intake. A study by Pardo et al. on an 
activity-based anorexia (ABA) model showed similar 
results, with increased ghrelin secretion and decreased 
insulin sensitivity. In the present study also there 
was an increase in circulating total ghrelin from the 
third day of anorexia, but a loss of insulin sensitivity 
was observed during the first day, evident from high 
glucose levels [22]. Plasma CCK and GLP-1 decreased 
immediately after hypoxia exposure, which may be 
due to the decrease in food intake as they are secreted 
upon ingestion of food [23]. Ghrelin expression is re-
ported to increase upon fasting to induce hunger by 
acting on the GHS receptor in the hypothalamus [1]. 
On exposure to hypoxia, a slight increase in ghrelin 
and ghrelin receptor was observed in the stomach. 
Our results show that reduced food intake failed to 
sufficiently increase ghrelin and its receptor to prevent 
anorexia during hypoxia. The GOAT expression was 
low in stomach tissue during the first day of hypoxia 
but it tripled on day 3 and day 7. This result may 
explain why the initial increase in total ghrelin and 
ghrelin receptor in the stomach was not sufficient to 
improve appetite. The rise in plasma ghrelin from 
day 3 onwards might have taken effect due to its 
acylation by increased GOAT expression and hence 
might have been reflected as an improvement in food 
intake towards the end of hypoxic exposure. During 
anorexia ghrelin levels are supposed to increase in 
the circulation due to low nutritional availability, but 
in the present study anorexia induced pre-proghrelin 
at 6 hours of hypoxia in stomach tissue while cir-
culating levels raised only after the third day. The 
reason behind this delayed increase in plasma total 
ghrelin might also be attributed to the high plasma 
glucose observed during the first day of hypoxia as 
it is shown that elevated plasma glucose suppresses 
ghrelin secretion [24]. Other gut hormones GLP-1 and 
CCK are known to inhibit ghrelin secretion [25], but 
in this study it is unlikely that these hormones could 
have had an effect on ghrelin levels because both of 
these hormones decreased in response to low nutrient 
intake. Increasing ghrelin expression and activating 
GOAT on the first day might prevent loss of appetite 
in a hypoxic environment. CCKAR receptor reduced 
in the stomach as well as liver, which might be due to 
reduced circulating CCK levels during hypoxia. 
PPARα is known to promote fatty acid oxidation 
in the liver and it is upregulated during fasting. Free 
fatty acid, which arises from lipolysis in the adipose 
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tissue, acts as an activating ligand for PPARα [26]. The 
absence of PPARα during fasting lead to hypogly-
caemia and higher FFA [27, 28]. Like PPARα, PPARδ 
also promotes fatty acid oxidation in the liver but it 
decreases glucose production, while PPARα stimu-
lates gluconeogenesis [26]. Activation of PPARδ using 
ligands prevented weight gain [29]. Our results show 
a reduction in PPARα and PPARδ protein levels in the 
stomach upon hypoxic exposure, which might have an 
impact in the energy balance. An increase in PPARα 
and PGC1α expression in the liver was as expected 
because earlier reports stated that fasting induces its 
expression [18] and its increase might have activated 
the gluconeogenic pathway leading to an increase in 
blood glucose levels during hypoxia. Increased PPARδ 
in the liver from the seventh day of exposure might 
explain the continued weight loss even though food 
intake improved on the first day of hypoxia. The in-
crease in PPARδ might also be attributed to the normal 
blood glucose from the seventh day onwards, which 
was high on the first day. 
Hence, from the present study it can be concluded 
that ghrelin secretion is not sufficiently stimulated by 
reduced food intake during hypoxia and might be an 
important reason for the loss of appetite. CCK and 
GLP-1 were secreted in response to the amount of food 
consumed. The metabolic function of the liver in the 
maintenance of blood glucose and fatty acid might have 
been impaired due to the altered expression of PPARs 
and PGC1s. The study revealed that targeting PPARα 
and PGC1α during initial days and PPARδ in later days 
of hypoxia exposure might alleviate the disturbances in 
the energy homeostasis and prevent anorexia at high 
altitude.   
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Figure 3. Western blot and PCR in stomach tissue of hypoxia exposed and control rats. A. There was an increase in pre-proghrelin 
and ghrelin receptor and a decrease in CCKAR, PPARα, and PPARδ protein levels, and B. An increase in GOAT mRNA levels during 
hypoxia exposure. *P < 0.05, **P < 0.01, ***P < 0.001
Rycina 3. Western blot i PCR w tkance żołądka u szczurów poddanych i niepoddanych działaniu hipoksji. A. Odnotowano wzrost 
pre-progreliny, receptora greliny i obniżenie CCKAR, stężenie białek PPARα i PPARδ oraz B. wzrost stężenia GOAT mRNA podczas 
poddania działaniu hipoksji. *P < 0,05; **P < 0,01; ***P < 0,001
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Figure 4. Western blot and PCR in liver tissue of hypoxia-exposed and control rats. A. Western blot results showed decreased CCKAR 
and initial increase in PPARδ during hypoxia exposure. B. Semiquantitative PCR results showed an increase in PPARα and PGC1α 
mRNA on exposure to hypoxia. *P < 0.05, ***P < 0.001
Rycina 4 Western blot i PCR w tkance wątroby u szczurów poddanych i niepoddanych działaniu hipoksji. A. Wyniki western blot 
wykazały obniżony poziom CCKAR i początkowy wzrost PPARδ podczas trwania hipoksji. B. Wyniki półilościowej PCR wykazały 
wzrost PPARα i PGC1α mRNA podczas poddania działaniu hipoksji. *P < 0,05; ***P < 0,001
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